A clinical study conducted in India and published in the peer reviewed journal Food & Nutrition Research reported that adults with irritable bowel syndrome (IBS) showed improvement from co-existing depression when they took a probiotic strain Bacillus coagulans MTCC 5856 (2 billion spores per day); subjects of the study given a placebo did not report the same improvement.
This study, Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, double blind, placebo controlled, multi-centre, pilot clinical study, published in Food & Nutrition Research, provides evidence of clinical efficacy of B. coagulans MTCC 5856 in patients experiencing major depression symptoms with IBS and supports the hypothesis that the modification of microbial ecology in human gut by supplementing probiotics may be an alternative strategy to ameliorate or prevent depression. The study demonstrates that consumption of probiotic B. coagulans MTCC 5856 may improve gut symptoms and psychological issues i.e. major depression, sleeplessness, and dementia in IBS. This provides new opportunity not only to help patients suffering from gastrointestinal related disorders but also the patients suffering from extra-intestinal disorders such as major depression, quality of sleep and dementia.
IBS is characterized by the alterations in bowel function or discomfort, abdominal pain or bloating and diarrhea or constipation, with the prevalence estimated between 9% and 23% in the population across the world. IBS patients are also frequently affected by chronic anxiety, mood disorders and major depression.
This 90 day randomized, double blind, placebo controlled trial involved 40 adults with IBS co-existing with major depressive disorder. Twenty participants took a daily dose of the probiotic B. coagulans MTCC 5856 (2 billion spores per day) and other 20 subjects were on placebo. At 90 days, subjects receiving B. coagulans MTCC 5856 (2 × 109 spores/day) reported a significant change/decrease in their depression clinical symptoms along with decrease in IBS as compared to subjects receiving placebo. It was also noticed that the subjects in the B. coagulans MTCC 5856 group reported improvement in sleeplessness and to a lesser extent for dementia.
The study reported no clinically significant changes in vital signs, no abnormal lab values (biochemistry and hematology), and also no Serious Adverse Events or Significant Adverse Events associated with the consumption of probiotic B. coagulans MTCC 5856, suggesting its excellent clinical safety in patients suffering from major depression with IBS.
These clinical findings indicate that B. coagulans MTCC 5856 may be an important new treatment option for major depressive disorder in IBS patients and opens a new avenue for the probiotic use in gut and psychological conditions.
Sabinsa undertook this study after Shaheen Majeed, President-worldwide, noticed depression to be commonly reported among subjects suffering from IBS at the time of screening for the first clinical trial conducted on LactoSpore® for the treatment of IBS predominant diarrhea and those patients were excluded in the study (Majeed et al. 2016. Nutrition Journal 15:21. https://doi.org/10.1186/s12937-016-0140-6).
Original Research: Full open access research for “Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, double blind, placebo controlled, multi-centre, pilot clinical study” by Muhammed Majeed, Kalyanam Nagabhushanam, Sivakumar Arumugam, Shaheen Majeed and Furqan Ali in Food & Nutrition Research. Published online July 04 2018. DOI: https://doi.org/10.29219/fnr.v62.1218
LactoSpore® is Sabinsa’s clinically validated and commercial probiotic preparation containing L(+) lactic acid producing microbial preparation from Bacillus coagulans, MTCC 5856 (earlier known as Lactobacillus sporogenes). For more information, visit www.lactospore.com.
